GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/Impact of Adenoma Detection Rate on Prevalent Colorectal Cancer Identification in a National Colonoscopy Registry
135

Impact of Adenoma Detection Rate on Prevalent Colorectal Cancer Identification in a National Colonoscopy Registry

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated December 1, 2025

The study investigated the impact of adenoma detection rate (ADR), a key quality metric for colonoscopy, on the identification of prevalent colorectal cancer (CRC) during colonoscopy. While ADR is known to inversely correlate with post-colonoscopy CRC, its association with detecting existing CRC at the time of the procedure was less clear. Using data from a large national colonoscopy registry, the researchers analyzed both screening colonoscopies and those conducted after abnormal fecal test results.

The primary aim was to assess the relationship between individual endoscopists' ADR and the likelihood of identifying CRC present during the procedure. Secondary analyses examined related quality indicators, such as detection of sessile serrated lesions and advanced precancerous lesions, while considering patient demographics, procedural factors, and endoscopist-specific variables.

The findings revealed a strong positive association between higher ADR and increased detection of prevalent CRC in both screening and follow-up colonoscopies. Endoscopists with lower ADRs consistently missed more cancers, regardless of their ability to detect sessile serrated lesions. Detection of advanced precancerous lesions also mirrored ADR patterns, suggesting overlapping skills in identifying adenomas and invasive cancers.

The study concluded that many post-colonoscopy CRCs might arise from cancers missed during the initial examination, not just from undetected precursor lesions progressing over time. These results underscore the importance of maintaining high ADRs and enhancing colonoscopy quality improvement initiatives. Improving ADR can lead to better recognition of early-stage cancers and subtle neoplastic lesions, ultimately reducing the burden of CRC.

Related Q&A

136

Enfortumab vedotin for gastric and esophageal cancers

Enfortumab vedotin (EV), a Nectin-4–directed antibody–drug conjugate, has been evaluated for its antitumor activity and safety in patients with heavily pretreated gastric and esophageal cancers through the EV-202...

137

VEGF bispecific fast lane

The term "VEGF bispecific fast lane" refers to the accelerated development and competitive landscape surrounding VEGF bispecific antibodies in oncology, particularly in the context of Pfizer's strategic initiatives...

138

Radiofrequency ablation for malignant biliary obstruction

Radiofrequency ablation (RFA) is a minimally invasive procedure that uses heat generated by high-frequency electrical currents to destroy abnormal or malignant tissue. In the context of malignant biliary...

139

Big Bang Moment

The "Big Bang" moment, as described in the context of bowel cancer research, refers to a defining early event in the development of the cancer that determines how...

140

FDA grant Fast Track Designation to a new drug combination for metastatic CRC

Yes, the FDA has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer (CRC). This combination includes alnodesertib (an ATR inhibitor) and low-dose irinotecan....

141

Bemarituzumab in First-Line Gastric Cancer — FORTITUDE Trials

Bemarituzumab is a first-in-class monoclonal antibody that targets FGFR2b (fibroblast growth factor receptor 2b), a key driver in a subset of gastric cancers characterized by FGFR2b overexpression. The...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer